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Abstract
Endogenous mechanisms leading to host protection and resolution of infections without 
immunosuppression are of wide interest1,2. Here we elucidated the structures of four new host-
protective molecules produced in neutrophil-endothelial co-cultures, and present in human and 
mouse tissues after sterile inflammation or infection. These bioactive molecules contained 
conjugated triene and diene double bonds with each carrying a 13-carbon position alcohol and 
were derived from n-3 docosapentaenoic acid (DPA, C22:5). These compounds, termed 13-series 
resolvins (RvT), demonstrated potent protective actions increasing mice survival during 
Escherichia coli infections. RvT also regulated human and mouse phagocyte responses 
stimulating bacterial phagocytosis and regulating inflammasome components. Their biosynthesis 
during neutrophil-endothelial cell interactions was initiated by endothelial cyclooxygenase-2 
(COX-2) and increased by atorvastatin via S-nitrosylation of COX-2. The actions of atorvastatin 
and RvT were additive in E. coli infections in mice where they accelerated resolution of 
inflammation and increased survival >60%. These results document novel host protective 
molecules in bacterial infections, namely 13-series resolvins, derived from n-3 DPA via 
transcellular biosynthesis and increased by atorvastatin. These novel molecules regulate key innate 
protective responses in the resolution of infectious-inflammation.
Infections are a leading cause of mortality worldwide, with bacterial infections, including 
those caused by Escherichia coli, posing an urgent health concern1,2. The prevalent 
approach for treating bacterial infections is administration of antibiotics, but with the rise in 
antibiotic-resistant bacteria, there is a pressing need for new treatment strategies1,2. In 
response to infection, the host mounts inflammatory responses that when self-resolving are 
protective3–5. We previously characterized potent endogenous anti-inflammatory and pro-
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resolving mediators namely resolvins, protectins and maresins known as specialized pro-
resolving mediators (SPM)4. These are biosynthesized from n-3 essential fatty acids 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)4. Docosapentaenoic acid 
(n-3, DPA), the intermediate in DHA biosynthesis from EPA, accumulates in individuals6 
with single nucleotide polymorphisms in the gene encoding for fatty acid elongase-2 and is 
also the precursor for three new SPM families7.
During the resolution phase of a self-resolving acute inflammation, SPM are produced 
locally and exert protective actions on leukocytes stimulating clearance of apoptotic cells, 
debris and bacteria as well as promote tissue regeneration4,8. Signals produced in the early 
phase of infectious-inflammation can determine the amplitude and duration of the 
inflammatory response9. Hence, novel mediators that may be produced during early phases 
of self-resolving infections to fine-tune the initial response and promote resolution are of 
general interest.
Neutrophils are the first line of defense against invading pathogens10,11. They are rapidly 
recruited from the vasculature to site(s) of infection and participate in bacterial containment 
and clearance8. One of the first steps in recruitment is neutrophil capture onto the vascular 
endothelium10. To identify new molecules that may exert host protective actions produced 
during this key step and since resolvins and protectins enhance the host clearance of 
bacterial infections8, we obtained fractions from co-incubations of these cell types using 
C18 solid phase extraction (see methods). Given that E. coli infections are an urgent world 
wide health concern with at least ~270,000 new cases reported per year in the United states 
alone12 we next the assessed the actions of these fractions in E. coli infections in mice. 
When administered intravenously immediately prior to E. coli inoculation isolates from 
these human neutrophil-endothelial cell co-incubations significantly enhanced survival from 
lethal E. coli infections (Fig. 1a; p<0.05) and did not display direct antibacterial activity 
(Supplementary Fig. 1a).
To characterize and elucidate bioactive molecule(s) within these fractions and deduce their 
structure(s), we initially used liquid chromatography tandem mass-spectrometry (LC-MS-
MS) based lipid mediator (LM)-metabololipidomics. Along with classic eicosanoids and 
SPM, we identified previously unknown molecules in fractions that showed activity from 
neutrophil-endothelial cell co-incubations. These gave four distinct MS-MS spectra and 
retention times characteristic of a 22-carbon backbone with five double bonds suggesting 
DPA was the precursor7. Using MS-MS fragmentations we deduced the structures of these 
new n-3 DPA derived bioactive molecules as: 7,13,20-trihydroxy-docosapentaenoic acid, 
7,12,13-trihydroxy-docosapentaenoic, 7,8,13-trihydroxy-docosapentaenoic acid and 7,13-
dihydroxy-docosapentaenoic acid (Fig. 1b and Supplementary Figs. 1b and 2a–d). Their 
assignments were confirmed using physical characteristics including MS-MS of different 
chemical derivatives and reactivity (i.e.18O2 incorporation, acid methanol trapping and 
methyl ester vide infra and online methods) for each product. Co-incubations of neutrophil-
endothelial cells with n-3 DPA, but neither DHA nor EPA precursors to SPM4,9, increased 
their amounts 30–50% (Supplementary Fig. 2e). Thus these new bioactive structures were 
denoted 13-series resolvins (RvT), RvT1, RvT2, RvT3 and RvT4 respectively, since each 
carried a carbon-13 position alcohol from their biosynthetic origin (Supplementary Fig. 1b).
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Since in humans exercise leads to a self-resolving inflammatory state marked by increases in 
plasma lipid mediators13, we investigated RvT production in healthy volunteers during 
exercise. Significant increases in peripheral blood RvT were obtained when compared to 
pre-exercise levels (Fig. 1c, Supplementary Table 1a; p<0.05). Their amounts were 
comparable in magnitude to those from the AA, EPA or DHA bioactive-metaboIomes, 
namely prostaglandins, leukotriene B4, resolvins, protectins and maresins (Supplementary 
Table 1b). RvT were also present in human peripheral blood from sepsis patients (Fig. 1d, 
Supplementary Table 2) and when compared to amounts in plasma from healthy volunteers 
and those in a human plasma composite obtained from the National Institutes for Standards 
and Technologies (SRM1950). Resolvins and lipoxins were also increased in sepsis patient 
plasma when compared to both healthy volunteer plasma and the SRM1950 plasma 
composite (Supplementary Table 3).
We then assessed the temporal regulation of RvT during bacterial infections in mice. FVB 
mice challenged with E. coli 105 CFU E. coli/mouse had a self-resolving (i.e. self-limited) 
inflammatory response with PMN numbers reaching a maximum at ~12h followed by their 
decline8. RvT were rapidly formed during the initiation phase of inflammation with amounts 
in peripheral blood reaching a maximum at 4h that subsequently declined (Fig. 1e). By 
comparison, mediators derived from AA-, EPA- and DHA-derived mediators also increased 
at 4h with the majority reaching maximum at 12h. These included RvD2 and LXB4 
(Supplementary Table 4). Notably, RvT were >60% lower in peripheral blood from mice 
challenged with a higher E. coli burden that was non-lethal but caused increased 
inflammation with delayed resolution (107 CFU/mouse; Fig. 1f).
We speculated based on human neutrophil-endothelial cell co-incubations that RvT were 
products of transcellular biosynthesis because these co-incubations gave appreciable 
amounts of RvT1, RvT2, RvT3 and RvT4 (Supplementary Fig. 2f). Chiral LC-MS-MS 
demonstrated that endothelial cells incubated with n-3 DPA gave increased 13R-
hydroxy-7Z,10Z,14,16Z,19Z-docosapentaenoic acid (13R-HDPA; Supplementary Fig. 3a–
d) when compared to cells kept in culture medium alone. Since IL-1β and TNF-α up-
regulate endothelial COX-2 expression14, which converts DHA to 13-hydroxy-
docosahexaenoic acid9, we questioned whether endothelial COX-2 also converts n-3 DPA to 
produce 13-HDPA. Incubations of endothelial cells with celecoxib, a COX-2 selective 
inhibitor, or transfection of endothelial cells with shRNA targeting COX-2, each led to 
significant reductions in endothelial cell derived 13-HDPA (Supplementary Fig. 3e, f, 
p<0.05), indicating a role for COX-2 in 13-HDPA production. Incubations of n-3 DPA with 
human recombinant COX-2 gave 13R-HDPA (Supplementary Fig. 3g) with KM=3.1±1.3μM 
(Supplementary Fig. 3h), suggesting that n-3 DPA is converted to 13R-HpDPA by 
endothelial COX-2. This intermediate or its reduced alcohol form may then be donated to 
neutrophils that convert the intermediate(s) to RvT. This proposed biosynthetic route and the 
RvT structures were corroborated by assessing UV chromophores, MS-MS fragmentation 
spectra for methyl-ester derivatives (Supplementary Fig. 4), molecular oxygen (18O2) 
incorporation (Supplementary Fig. 5) and acid-alcohol trapping of epoxide intermediates 
(Supplementary Fig. 6). These results indicate that COX-2 derived 13-HDPA is converted 
via lipoxygenation in human neutrophils to RvT1, RvT2, RvT3 and RvT4.
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Atorvastatin is protective in bacterial infections in mice 15 and regulates COX-216. Hence 
we next questioned whether this statin regulates RvT biosynthesis. Incubation of neutrophil-
endothelial cell co-cultures with atorvastatin, at concentrations (0.03–30μM) relevant to 
those reached in humans17, led to dose-dependent increases in RvT (Fig. 2a). Fractions from 
these co-incubations significantly increased survival in mice during E. coli infections when 
compared to fractions from neutrophil-endothelial cell co-cultures without atorvastatin (Fig. 
2b; p<0.05) and those from either neutrophil or endothelial cells incubated separately with 
atorvastatin (Fig. 2b). Celecoxib significantly reduced RvT in these incubations (Fig. 2c; 
p<0.05) and abolished the protective actions of isolated fractions obtained from neutrophil-
endothelial cell co-incubations with atorvastatin (Fig. 2c).
Administration of L-NG-Nitroarginine Methyl Ester (L-NAME) prior to atorvastatin 
significantly reversed atorvastatin-mediated increases in plasma RvT (Fig. 2e; p<0.05) and 
increased neutrophil recruitment to the peritoneum during mouse infections (Fig. 2f). With 
human endothelial cells NOS inhibitors (L-NAME and 1400W) also significantly reduced 
atorvastatin-mediated RvT increases by 70–90% (Supplementary Fig. 7a; p<0.05). In 
addition, incubation of human recombinant COX-2 (hrCOX-2) with S-nitrosoglutathione, 
which S-nitrosylates COX-218 (Supplementary Fig. 7b), gave increased 13R-HDPA and 
hrCOX-2 catalytic activity (Fig. 2g) compared to native COX-2. These results indicated that 
atorvastatin increased RvT production via S-nitrosylation of endothelial COX-2.
Next we tested the bioactions of these molecules with human leukocytes. RvT were 
produced using recombinant enzymes and primary human neutrophils and isolated (see 
methods for details) using reverse phase high-pressure liquid chromatography (RP-HPLC). 
RvT1 and RvT4 were isolated to apparent homogeneity based on their appearance beneath a 
single RP-HPLC peak and characteristic UV chromophores. RvT2 and RvT3 were tested 
together since they eluted in the same RP-HPLC fractions. RvT1 (1pM–10nM) dose-
dependently increased E. coli phagocytosis and production of intracellular reactive oxygen 
species (ROS) in human macrophages (Fig. 3a, b) as well as efferocytosis of apoptotic 
neutrophils (Fig. 3c), a key step in the resolution of inflammation4. Similar actions were 
obtained with human neutrophils, where RvT1 (1pM–10nM) dose-dependently increased E. 
coli phagocytosis (20–55%) and intracellular ROS (20–40%; n=4 donors). RvT1 (10pM–
10nM) also dose-dependently blocked human macrophages activation of inflammasome 
components, decreasing caspase-1 and IL-1β expression and extracellular lactate 
dehydrogenase activity (LDH; Supplementary Fig. S8a–c). Similar results were obtained 
with RvT4 and RvT2 plus RvT3 (Supplementary Fig. 8a–c).
Given RvT were each identified in human and murine infections, we assessed their 
combined actions in E. coli infections in mice, administering a mixture of RvT1, RvT2, 
RvT3 and RvT4 (RvT1-4) immediately prior to intraperitoneal E. coli inoculation. Twelve 
hours later these molecules afforded dose-dependent protection against hypothermia, limited 
further neutrophil recruitment to sites of inflammation, increased bacterial phagocytosis by 
peritoneal leukocytes (Fig. 3d–f), and reduced monocyte/macrophage expression of 
caspase-1, IL-1β levels and LDH activity (Supplementary Fig. 8d–f) without exerting direct 
antibacterial activities (Supplementary Fig. 9a). RvT also reduced systemic inflammation as 
demonstrated by reduced platelet-leukocyte aggregates7 (Supplementary Fig. 8g). LM 
Dalli et al. Page 4
Nat Med. Author manuscript; available in PMC 2016 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
metabololipidomics of plasma from mice given RvT1-4 (500ng/mouse) gave significant 
reductions in TxB2, PGD2 and PGE2 (Supplementary Fig. 9b; p<0.05) that are elevated by 
inflammasome activation (i.e. eicosanoid storm) during infections19. RvT also significantly 
increased exudate macrophage efferocytosis (Fig. 3g; p<0.05). Moreover, administration of 
RvT1-4 2h after E. coli inoculation dose-dependently increased mice survival (Fig. 3i).
Prolonged statin use is linked with a number of adverse effects including inflammasome 
activation20 and diabetes21. Therefore we next tested whether RvT could reduce the 
effective dose of atorvastatin needed to clear E. coli infections thus reducing statin exposure. 
Co-administration of RvT1-4, (~12.5ng/mouse each), and a sub-threshold dose of 
atorvastatin (0.5μg/mouse) immediately prior to E. coli inoculation significantly protected 
mice from hypothermia, reduced neutrophil recruitment (~50%; p<0.05), local and systemic 
bacterial loads, exudate IL-1β levels (~45%; p<0.05) and LDH activity (~40%; 
Supplementary Fig. 10a–e; p<0.05). This co-treatment also significantly increased bacterial 
phagocytosis by exudate leukocytes (~90%; p<0.05) and efferocytosis by exudate 
macrophages (~90%; Supplementary Fig. 10f, g; p<0.05). Thus suggesting that RvT may 
reduce the exposure to atorvastatin therapy potentially limiting some of the unwanted side 
effects of statins observed at higher statin doses20,21.
In order to assess whether this treatment regime was also protective in a therapeutic setting, 
we treated mice with atorvastatin (0.5 μg/mouse) and/or a mixture of RvT1-4 (50 ng/mouse) 
2h after E. coli inoculation. Co-administration of atorvastatin and RvT significantly reduced 
neutrophil recruitment to the peritoneum and reduced exudate bacterial loads 
(Supplementary Fig. 10h; p<0.05). To gain insight into potential mechanism(s) activated by 
atorvastatin and RvT, we investigated expression of host protective22,23 and pro-
inflammatory factors24 regulated by atorvastatin. In mice given 0.5 μg/mouse statin alone, 
we measured increases in host-protective PGI2 and 15-deoxy-Δ-12,14-PGJ2, (Supplementary 
Fig. 10i) whereas in endothelin-1 and plasminogen activator inhibitor-1 were reduced, 
molecules associated with a pro-inflammatory status (Supplementary Fig. 10j). RvT 
administration (50ng/mouse) regulated some of these molecules, although to a lesser extent 
(~30–60% lower) than atorvastatin. Co-administration of atorvastatin and RvT1-4 
significantly reduced these molecules when compared to vehicle- or RvT-treated mice 
(Supplementary Fig. 10j, k; p<0.05). Peripheral blood eicosanoids were also reduced upon 
RvT1-4 administration (Supplementary Fig. 10k), effects that were only in part shared with 
atorvastatin.
Given these protective actions we assessed whether co-administration of RvT and 
atorvastatin could accelerate resolution of infections. Administration of RvT1-4 (50 ng/
mouse) together with atorvastatin (0.5 μg/mouse) at peak neutrophil infiltration (12h) 
significantly accelerated exudate neutrophil clearance, increased bacterial phagocytosis by 
exudate leukocytes (~50%; p<0.05), accelerated resolution of inflammation, shortening the 
resolution interval from ~20h to ~8h (Fig. 4a and Supplementary Fig. 10). Co-administration 
of RvT1-4 with atorvastatin at both high (500ng RvT plus 5μg atorvastatin) and low doses 
(50ng RvT plus 0.5μg atorvastatin) increased survival of mice compared to treatment with 
atorvastatin alone (Fig. 4b). Together these results suggest that during infections RvT lower 
the effective dose of atorvastatin.
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In summary, using LC-MS-MS based lipid mediator-metabololipidomidics, we elucidated 
the structures of four new bioactive molecules termed RvT formed by transcellular 
biosynthesis 4,9,14 during human neutrophil-endothelial cell interactions (Supplementary 
Table.5 and Supplementary Fig. 1b). RvT production was elevated during self-resolving 
inflammatory challenge in humans and mice, and down-regulated in mice during delayed 
resolution of infections. These 13-series resolvins from n-3 DPA exerted both anti-
inflammatory and potent pro-resolving activities regulating host responses during E. coli 
infections in mice and phagocytosis by isolated human cells, thereby fulfilling criteria as 
immunoresolvents4: namely, they stimulate the cardinal signs of resolution including 
expurgatio reliquiorum (clearance of debris), expurgatio contagionem agentis (clearance of 
infective agents), doloris absentia (analgesia) and muneris lucrum (gain of function)4. Given 
the extensive size of the vascular-endothelial system in humans and the abundance of 
neutrophils within the circulation, RvT formation during early stages of self-resolving acute 
inflammation and their regulation by atorvastatin, could provide a molecular basis for the 
development of new treatment strategies for infectious-inflammation. In addition, RvT may 
also serve as statin-markers and mediators of their actions during resolution responses.
Online Methods
E. coli peritonitis
All animal experiments were conducted in accordance with the Harvard Medical Area 
Standing Committee on Animals (protocol no. 02570). Mice (male FvB, 6–8 weeks old, 
Charles River, fed lab diet containing essential fatty acids as from supplier) were 
anesthetized with isoflurane and microbial peritonitis initiated. Briefly, test compounds or 
vehicle were injected i.p. or i.v. 5 min prior to live E. coli (serotype O6:K2:H1; 1×105 or 
1×107CFU/mouse). At designated time intervals mice were harvested, blood was collected 
via cardiac puncture in heparin, and peritoneal exudates were collected in 4ml of PBS. The 
cellular composition in the exudates was determined using Turks solution and light 
microscopy, and by flow cytometry. For flow cytometry, exudate cells were incubated with 
anti-mouse CD16/CD32 (eBiosciences, 20min, 4°C, in PBS containing 5% fetal calf serum-
staining solution), followed by incubation with FITC-conjugated anti-mouse Ly6G antibody 
(clone:1A8, eBiosciences), PE-conjugated anti-mouse F4/80 antibody (clone:BM8, 
eBiosciences) and PerCP-Cy5.5-conjugated anti-mouse CD11b antibody (clone:M1/70, 
eBiosciences) for 30min (4°C, in staining solution). To assess bacterial phagocytosis in 
peritoneal exudate leukocytes, exudate cells were incubated with PerCP-Cy5.5-conjugated 
anti-mouse CD11b antibody (30 min, 4°C, in staining solution), then fixed and 
permeabilized using BD Perm/Wash™ Buffer (BD Biosciences) following manufacturer’s 
instructions and incubated with FITC-conjugated anti-E. coli antibody (GenTex, 30 min, 
4°C, in BD Perm/Wash™ Buffer). Efferocytosis in infectious exudates was assessed by 
incubating exudate leukocytes with PE-conjugated anti-mouse F4/80 antibody (30 min, 4°C, 
in staining solution), then fixed and permeabilized using BD Perm/Wash™ Buffer (BD 
Biosciences) and incubated with FITC-conjugated anti-mouse Ly6G antibody (30 min, 4°C, 
in BD Perm/Wash™ Buffer). Body temperatures were assessed using an Infrared 
thermometer (Fluke). Bacterial counts in peripheral blood and inflammatory exudates were 
determined by overnight cultures (37°C) of serially diluted samples on LB agar plates. 
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Caspase 1 levels were assessed by incubation of exudate cells with PerCP-Cy5.5-
conjugated anti-mouse CD11b antibody (30 min, 4°C, in staining solution), then fixed and 
permeabilized using BD Perm/Wash™ Buffer (BD Biosciences), incubated with anti-caspase 
1 antibody (Abcam, 30 min, 4°C, in BD Perm/Wash™ Buffer) followed by anti-rabbit Alexa 
488 conjugated antibody (Life Technologies, 30 min, 4°C, in BD Perm/Wash™ Buffer). 
IL-1β levels were determined in cell-free supernatants using an anti-mouse IL-1β ELISA 
(Abcam) following manufacturer’s instructions. Lactate dehydrogenase activity was 
measured in cell-free supernatants assessing the formation of NADH from NAD+ using a 
Lactate Dehydrogenase Assay kit (Sigma) following manufacturer’s instructions.
In select experiments resolution indices were calculated as in 27. ψmax, maximal PMN 
numbers in exudates; Tmax, time point when PMN numbers reach maximum; R50, 50% of 
maximal PMN numbers; T50, time point when PMN numbers reduce to 50% of maximum; 
Ri (resolution interval), T50-Tmax, time period when 50% PMN are lost from the exudates. 
To assess the proresolving actions of the test products, these were administered 12h after E. 
coli (105 CFU) inoculation, and resolution indices were assessed.
For some experiments, mice were administered via i.p. injection RvT1, RvT2, RvT3 and 
RvT4 (that were isolated as detailed below and combined as a mixture at a ratio of 2:1:1:8 
respectively) 2h after E. coli inoculation. Blood and lungs were harvested 6h after E. coli 
inoculation. Blood was employed to determine peripheral blood eicosanoid levels as detailed 
below. Lungs were placed in TriReagent (Invitrogen), RNA isolated following 
manufacturer’s instructions and relative mRNA expression for mouse endothelin-1 and 
plasminogen activator inhibitor-1 determined using Qiagen SYBR® Green ROX qPCR 
mastermix and QuantiTect® Primer assays following manufacturer’s instruction and using 
mouse Glyceraldehyde 3-phosphate dehydrogenase as house keeping gene. mRNA 
expression was determined using an ABI PRISM 7900HT system (Applied Biosystems). In 
determined experiments, peritoneal exudates were obtained from mice 12h after E. coli 
inoculation and bacterial loads along with leukocyte counts determined as detailed above.
For survival studies, mice were administered test compounds or biological isolates from 
neutrophil-endothelial cell (HUVEC) co-incubations via i.p. injection 5 min prior to 
inoculation with E. coli (2.5×107 CFU), and survival was assessed. In designated 
experiments, RvT1, RvT2, RvT3 and RvT4 were isolated as detailed below, combined as a 
mixture at a ratio of 2:1:1:8 respectively, and were administered via i.p. injection 2h after E. 
coli (2.5×107 CFU); survival was assessed for the subsequent 94h. In separate experiments, 
0.5μg (lower dose) or 5μg (higher dose) of atorvastatin was administered via i.p. with or 
without RvT1, RvT2, RvT3 and RvT4, which were isolated and quantified as detailed 
below, combined as a mixture (at a ratio of 2:1:1:8) at the indicated concentrations 3h after 
E. coli (2.5×107 CFU) inoculation, and survival assessed for the next 93h.
In a separate set of experiments, mice were inoculated with E. coli; after 60 min they were 
given L-NAME (24mg/kg) and 5 min later atorvastatin (5μg) via i.v. injection. Plasma was 
obtained after 5h via cardiac puncture and LM levels were investigated by lipid mediator 
metabololipidomics. For all animal experiments mice were randomized to vehicle or 
treatment groups without blinding.
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Biosynthesis and lipid mediator metabololipidomics
Isolated n-3 DPA (Cayman Chemicals) was incubated with human recombinant COX-2 
(Cayman Chemicals; in 0.1M Tris-HCl, pH 8.0, 20μM porcine hematin, 0.67mM phenol) for 
30min at RT. Incubations were stopped with 1 volume of methanol and products extracted 
using diethyl ether as in 28. 13-HDPA was isolated using RP-HPLC (1100 Series; Agilent 
Technologies) and an Agilent C18 Poroshell column (2.7μm × 4.6 mm × 150 mm) with a 
mobile phase consisting of methanol/water (60:40, vol:vol) at 0.5 ml/min that was ramped 
up to 98:2 (vol:vol) for 20 min. 13-HDPA (10μM) was incubated with potato 5-LOX 
(Cayman Chemicals) for 30 min (4°C, 0.1M phosphate buffer, pH 6.3, 0.03% Tween 20). 
Incubations were stopped with 1 volume of ice-cold methanol, products were reduced using 
NaBH4 (Sigma-Aldrich) and extracted as in 28.
Methanol (2 volumes) was added to cell incubations, plasma (mouse and human) and 
infectious exudates, and samples stored at −20°C until extraction. All samples for LC-MS-
MS-based metabololipidomics were extracted with solid-phase extraction columns as 
previously reported 29. Prior to sample extraction, deuterated internal standards (d4-PGE2, 
d5-LXA4, d4-RvD2, d4-LTB4 and d8-5S-HETE) representing regions of interest in the 
chromatographic analysis (500 pg each) were added to facilitate quantification. Extracted 
samples were analyzed by a LC-MS-MS system, Qtrap 6500 (AB Sciex) equipped with a 
Shimadzu SIL-20AC autoinjector and LC-20AD binary pump (Shimadzu Corp.). An 
Agilent Eclipse Plus C18 column (100×4.6mm×1.8μm) was used with a gradient of 
methanol/water/acetic acid of 55:45:0.01 (vol:vol:vol) that was ramped to 85:15:0.01 
(vol:vol:vol) over 10min and then to 98:2:0.01 (vol:vol:vol) for the next 8min. This was 
subsequently maintained at 98:2:0.01 (vol:vol:vol) for 2 min. The flow rate was maintained 
at 0.4ml/min. To monitor and quantify the levels of lipid mediators, a multiple reaction 
monitoring (MRM) method was developed with signature ion fragments (m/z) for each 
molecule monitoring the parent ion (Q1) and a characteristic daughter ion (Q3). 
Identification was conducted using published criteria where a minimum of 6 diagnostic ions 
were employed 29. Calibration curves were determined using a mixture of lipid mediators 
obtained via total organic synthesis, where these lipid mediators were not available (RvT1, 
RvT2, RvT3, RvT4 and 13-HDPA); known mediators with similar chromatographic 
properties (RvD2 for RvT1, RvD1 for RvT2 and RvT3; RvD5 for RvT4; 13-HDHA for 13-
HDPA) were used. Linear calibration curve for each compound was obtained with r2 values 
ranging from 0.98 to 0.99. Detection limit was ~0.1 pg. Quantification was carried out as 
in 29. To measure 6-keto-PGF1α levels, samples were extracted as outlined above, 
suspended in water, and 6-keto-PGF1α levels measured using a 6-keto-PGF1α ELISA 
(Neogen).
For chiral lipidomic analysis, a Chiralpak AD-RH column (150 mm × 2.1 mm × 5 μm) was 
used with isocratic methanol/water/acetic acid 95:5:0.01 (v/v/v) at 0.15 ml/min. To monitor 
isobaric monohydroxy docosapentaenoic acid levels, a multiple reaction monitoring (MRM) 
method was developed using signature ion fragments for each molecule as in 30.
In select experiments, RvT1, RvT2, RvT3 and RvT4 were incubated with diazomethane in 
ether, prepared as in 28 for 30 min at 37°C and products assessed by LC-MS-MS, operating 
the mass spectrometer in positive ion mode.
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In order to extract products from neutrophil-endothelial cell co-incubations for biological 
evaluation, 2 volumes of ice-cold methanol were added to stop the incubations and the 
samples placed at −20°C for at least 30 min to allow for protein precipitation. Products were 
then extracted using C18 SPE as detailed above and eluted using methyl formate. The 
solvent was then evaporated under nitrogen and products suspended in ethanol for biological 
evaluation.
13R-HDPA and 13S-HDPA were obtained by incubating 13-HDHA with Dess Martin 
Periodinane (0.03M in methylene chloride, 30min, RT); the resulting 13-oxo-DPA was then 
incubated with either (R)-2-methyl-CBS-oxazaborolidine or (S)-2-methyl-CBS-
oxazaborolidine as in 31.
In some experiments, human peripheral neutrophils (5×107 cells/ml) were incubated with 
13R-HDPA (1μM, 37°C, PBS pH 7.45) and E. coli (1×109 CFU/ml, 2 min, 37°C). 
Incubations were stopped with 2 volumes of acidified methanol (apparent pH 3), products 
extracted and profiled using LM metabololipidomics.
Human neutrophils (4×107 cells/ml) were incubated with 13R-HDPA (300nM) in PBS (pH 
7.45, 37°C) in an 18O2 enriched environment; E. coli (2×109 CFU/ml) were then added. The 
incubations were quenched after 30 min using 2 volumes of ice-cold methanol, then 
incubated with sodium borohydride (1μg/ml, 15min, 4°C), products extracted and profiled 
using LM metabololipidomics. The following MRM transitions were employed to monitor 
each of the new products: RvT1 - 381>145, RvT2 - 379>145, RvT3 - 227 and RvT4 - 363 
-145.
Whole blood from healthy volunteers (HV), who declared to exercise for at least 45 mins 2–
3 times per week and that they had not taken medications including nonsteroidal anti-
inflammatory drugs, ASA-containing products or statins 10 –14 days before venipuncture, 
was obtained after obtaining written consent in accordance with the Declaration of Helsinki 
and Partners Human Research Committee Protocol 1999P001279 for discarded materials 
(CNS). Participants rested for 5–10 min in a seated position prior to peripheral blood 
sampling pre-exercise. Immediately after, the exercise protocol commenced involving 10 
min warming up and stretching exercises followed by 30–45 min vigorous intensity 
continuous cycling or cross-training terminating the exercise when subjects reached ~90% 
of their theoretical maximum. This was calculated using the formula 220 – age in years as 
in 32. Blood was collected from these subjects within 15 min of exercise termination. All 
bloods were collected in heparin, then placed in 4 volumes of ice-cold methanol containing 
internal standards, and mediator levels were assessed by LC-MS-MS as detailed above.
Plasma from patients diagnosed with sepsis was obtained from Dx Biosamples (see Table S3 
for demographics). Plasma from healthy volunteers (HV) was collected as outlined above. 
Human reference plasma denoted SRM 1950 was purchased from the National Institute of 
Standards and Technology (NIST). Plasma from these patients and volunteers was placed in 
2 volumes of ice-cold methanol containing internal standards, and mediator levels assessed 
by LC-MS-MS as detailed above.
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Whole blood was collected in heparin at determined time intervals during E. coli infections 
in mice. This was then placed in 4 volumes of ice-cold methanol containing internal 
standards, and mediator levels assessed by LC-MS-MS as detailed above.
Neutrophil-endothelial co-incubations
Human umbilical endothelial cells (HUVEC; 8.5×105 cells/9.6cm2) were incubated with 
IL-1β (10ng/ml) and TNF-α (10ng/ml; 16h, 37°C, 5% CO2). Cells were then incubated with 
atorvastatin (30nM–30μM), celecoxib (25μM), L-NAME (25μM), 1400 W (10μM) or 
vehicle (PBS containing 0.01% DMSO) followed by addition of n-3 DPA (1μM, 1h, 37°C, 
5% CO2). In select experiments, 30 min after n-3 DPA addition, human neutrophils (1×107 
cells/ml) were added and cells incubated for 60 min (37°C, 5% CO2). Incubations were 
stopped with 2 volumes of ice-cold methanol and products extracted as detailed above. In 
determined experiments after the addition of human PMN, E. coli (5×108 CFU/ml) were 
also added and cells incubated 60 min (37°C, 5% CO2). Incubations were then stopped with 
2 volumes ice-cold methanol and LM profiles assessed using LM-metabololipidomics.
Endothelial cells were transfected with control scrambled sh-RNA or human COX-2 sh-
RNA (Origene) using jetPEI®-HUVEC (PolyPlus) following manufacturer’s instructions, 
and then incubated with IL-1β (10ng/ml) and TNF-α (10ng/ml; 16h, 37°C, 5% CO2). Cells 
were then incubated with n-3 DPA (1μM, 37°C, 5% CO2, in 0.1% EGM). Incubations were 
stopped with 2 volumes of ice-cold methanol and lipid mediators assessed by lipid mediator 
metabololipidomics.
Human neutrophil and macrophage phagocytosis and ROS
Macrophages were prepared from peripheral blood mononuclear cells (PBMC) purchased 
from Children’s Hospital Blood Bank, Boston, and phagocytosis was assessed as in 31. 
Briefly, macrophages (5×104 cells/well) were incubated with RvT1 (1pM–10nM), 1:1 
mixture RvT2 and RvT3 (1pM–10nM), RvT4 (1pM–10nM) or vehicle (0.1% EtOH in 
DPBS) for 15 min at 37°C, then fluorescent labeled apoptotic cells were added and cells 
incubated 45 min at 37°C. Extracellular fluorescence was quenched using Trypan blue (1:15 
dilution) and phagocytosis assessed using an M3 SpectraMax plate reader (Molecular 
Devices). In select experiments, macrophages (prepared as detailed above, 5×104 cells/well) 
or neutrophils (1×105 cells/well), obtained from human healthy volunteers and isolated as 
in 31 in accordance with Partners Human Research Committee Protocol (number 
1999P001297), were incubated with H2DCFDA (5μM, 30min, 37°C), excess dye was 
washed off and cells incubated with RvT1 (1pM–10nM), 1:1 mixture RvT2 and RvT3 
(1pM–10nM), RvT4 (1pM–10nM) or vehicle (0.1% EtOH in DPBS, 15 min, 37°C), then 
incubated with E. coli (1:50 leukocytes to E. coli, 45 min, 37°C). Intracellular reactive 
oxygen species were determined by measuring fluorescence using an M3 SpectraMax plate 
reader. To assess bacterial phagocytosis, macrophages (5×104 cells/well) or neutrophils 
(1×105 cells/well) were incubated with RvT1 (1pM–10nM), 1:1 mixture RvT2 and RvT3 
(1pM–10nM), RvT4 (1pM–10nM) or vehicle (0.1% EtOH in DPBS, 15 min, 37°C), then 
incubated with BacLight Green (Molecular Probes) labeled E. coli (1:50 leukocytes to E. 
coli, 45 min, 37°C). Extracellular fluorescence was then quenched using Trypan blue (1:15 
dilution), and phagocytosis was assessed using an M3 SpectraMax plate reader.
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Human macrophage caspase 1, IL-1β and lactate dehydrogenase
Human macrophages (1.5×104 cells/well) were incubated with RvT1 (10pM–10nM), 1:1 
mixture RvT2 and RvT3 (10pM–10nM), RvT4 (10pM–10nM) or vehicle (0.1% EtOH in 
DPBS, 15 min, 37°C), then E. coli (7.5×105 cells/well, in DPBS, 16h, 37°C). Caspase 1 
levels were assessed in macrophages by flow cytometry after cell fixing and 
permeabilization, staining with an anti-caspase 1 (Abcam; 4°C, 30min) and anti-rabbit-
Alexa 488 conjugated antibody (Molecular Probes; 4°C, 30min). IL-1β levels were 
determined in cell-free supernatants using an anti-human IL-1β ELISA (eBiosciences) 
following manufacturer’s instructions. Lactate dehydrogenase activity was measured in 
cell-free supernatants assessing the formation of NADH from NAD+ using a Lactate 
Dehydrogenase Assay kit (Sigma) following manufacturer’s instructions.
Recombinant enzyme incubations
Human recombinant COX-2 (10 units; Cayman Chemicals; in 0.1M Tris-HCl, pH 8.0, 20μM 
porcine hematin, 0.67mM phenol as in 33) was incubated with the indicated concentrations 
of AA or n-3 DPA (1h, RT) and absorbance at 235nM was investigated at 1 min intervals 
using a Cary UV-Vis Spectrophotometer (Agilent).
In designated experiments, n-3 DPA was incubated with hrCOX2, hrCOX-2 that was 
previously incubated with S-nitrosoglutathione (30 min RT), prepared by incubating 100mM 
glutathione with 100 mM sodium nitrite in 200mM hydrochloric acid at RT as in 34 or S-
nitrosoglutathione. After 20 min the incubations were quenched with methanol and 13-
HDPA levels were assessed using LC-MS-MS-based LM metabololipidomics.
COX-2 S-nitrosylation was assessed using a Pierce Western Blot S-nitrosylation Kit 
(Thermo Fisher) following manufacturer’s instructions, and total COX-2 levels were 
determined using a rabbit anti-COX-2 (Cell Signaling) antibody and a goat anti-rabbit-HRP 
conjugated antibody (eBioscience).
Anti-bacterial actions
Neutrophil-endothelial cell isolates, RvT1 (10μM), RvT2 plus RvT3 (10μM), RvT4 (10μM) 
or ampicillin (1 or 10mM) were placed on GF-C filters (Waters) that were then transferred 
onto LB agar plates containing E. coli (1×107 CFU). The zone of clearance was assessed 
after overnight incubation at 37°C.
Statistics
All results are expressed as means ± s.e.m.. We assumed normality and equal distribution of 
variance between the different groups analyzed. Differences between groups were compared 
using Student’s t test (2 groups) or 1-way ANOVA (multiple groups) followed by post hoc 
Bonferroni test. Survival in mouse experiments was demonstrated with Kaplan-Meier curves 
and analyzed using log-rank (Mantel-Cox). Investigators were not blinded to group 
allocation or outcome assessment. Sample sizes for each experiment were determined on the 
variability observed in preliminary experiments and prior experience with the experimental 
systems. The criterion for statistical significance was p<0.05.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Novel 13-series resolvins (RvT) from neutrophil-endothelial cell interactions are 
elevated in self-resolving inflammation
(a) Fractions were extracted from human neutrophil (PMN)-endothelial cell (EC) co-
incubations (see methods), administered to mice via i.v. injection 5 min prior to E. coli 
(2.5×107 CFU/mouse) inoculation and survival assessed. n=10 mice/group from three 
independent experiments. *p<0.05 vs. E. coli group. (b) Proposed structures from the novel 
13-series resolvins (RvT) identified in human PMN-EC co-incubations. (c) Blood was 
collected from healthy volunteers pre- and post-exercise (see methods) and amounts of RvT 
assessed using LC-MS-MS. n=4 healthy volunteers from four independent experiments. 
*p<0.05 vs. pre-exercise values. (d) Plasma was obtained from the NIST repository (SRM 
1950, d=3), collected from healthy volunteers (n=4) or patients diagnosed with sepsis (n=9), 
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and RvT assessed using LC-MS-MS. Results are expressed as mean±s.e.m. from two 
independent experiments. *p<0.05, **p<0.01 vs. SRM 1950, # p<0.05, ## p<0.01 vs. 
healthy volunteers. (e) Mice were inoculated with E. coli (1×105 CFU/mouse), blood was 
collected at the indicated intervals and RvT amounts assessed using LC-MS-MS. (f) Mice 
were inoculated with 1×105 CFU/mouse E. coli (self-resolving) or 1×107 CFU/mouse E. 
coli (delayed-resolving), blood was collected after 4h and RvT assessed using LC-MS-MS. 
Results for e, f are expressed as mean± s.e.m. n=4 mice per group from two independent 
experiments. *p<0.05 vs 0h blood levels (e) or vs. mice receiving a self-resolving inoculum 
(f).
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Figure 2. Atorvastatin increases protective actions of neutrophil-endothelia cell fractions during 
mouse infections and promotes RvT formation via S-nitrosylated COX-2
(a) RvT in human neutrophil-endothelial cells co-incubations with or without atorvastatin. 
Mean±s.e.m.; n=4 independent cell preparations. Four independent experiments. *p<0.05 vs. 
EC group. (b) Fractions extracted using C18 SPE (see methods) were administered to mice 
(i.v.) 5 min prior to E. coli (2.5×107 CFU/mouse) inoculation and survival assessed. n= 14–
17 mice/group. Three independent experiments. *p<0.05 vs. E. coli, #p<0.05 vs. E. coli plus 
hPMN-EC, §p<0.05 vs. E. coli plus hPMN plus atorv or E. coli plus hEC plus atorv. (c, d) 
Endothelial cells were incubated with IL-1β and TNF-α then vehicle, celecoxib and/or 
atorvastatin followed by n-3 DPA and hPMN. (c–d) Fractions were extracted (c) profiled 
using LM metabololipidomics. Mean±s.e.m. n=4 independent cell preparations/group. Three 
independent experiments. *p<0.05, **p<0.01 vs. incubations with IL-1β plus TNF-α alone; 
#p<0.05 vs incubations with IL-1β plus TNF-α atrovastatin. (d) administered prior to E. coli 
(2.5×107 CFU/mouse) and survival assessed. n=10 mice/group. Two independent 
experiments. *p<0.05 vs. E. coli; #p<0.05 vs. E. coli plus hPMN-EC plus atorv. (e–f) Mice 
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were inoculated with E. coli (1×105 CFU/mouse), 1h later L-NAME (24mg/kg) or vehicle 
(saline) was administered followed by atorvastatin (5μg/mouse, i.v., 5h) or vehicle (saline 
plus 0.01% EtOH). (e) Plasma RvT were quantified using LM metabololipidomics, (f) 
exudate cell numbers were enumerated. Mean±s.e.m. n=4 mice/group. Two independent 
experiments. *p<0.05 vs. E. coli. #p< 0.05 vs. E. coli plus atorvastatin. (g) Conversion of n-3 
DPA by human recombinant (hr) COX-2 and S-nitrosylated (SNO) hr-COX2. Mean±s.e.m. 
n=3 incubations. Three independent experiments.
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Figure 3. RvT regulate leukocyte responses and promote survival in infections
(a) Macrophages (5×104 cells/well) were incubated with the indicated concentrations of 
RvT1, RvT2 plus RvT3 (1:1 ratio), RvT4 or vehicle (PBS containing 0.01% EtOH; 15min, 
37°C, pH 7.45) then fluorescently labeled E. coli (2.5×106 CFU/well). (b) Macrophages 
(5×104 cells/well) were incubated with H2DCFDA (5μM, 30min, 37°C, pH 7.45); cells were 
washed, incubated with the indicated concentrations of RvT1, RvT2 plus RvT3 (1:1 ratio), 
RvT4 or vehicle (15 min, 37°C, pH 7.45), E. coli (2.5×106 CFU/well) were added and 
intracellular ROS levels determined. (c) Macrophages (5×104 cells/well) were incubated as 
in (a) with RvT, fluorescently-labeled apoptotic PMN (2.5×105 cells/well) were added and 
uptake assessed (see methods). Mean±s.e.m. n=4 donors. Three independent experiments. 
*p<0.05, **p<0.01 vs. macrophages plus vehicle. (d–g) Mice were given vehicle (saline 
containing 0.1% EtOH) or combination of RvT1, RvT2, RvT3 and RvT4 (ratio 2:1:1:8), 
each isolated and quantified by RP-UV-HPLC (see methods), via i.p. injection ~5min prior 
to E. coli (1×107 CFU/mouse) inoculation. 12h later (d) body temperatures, (e) peritoneal 
exudate neutrophil counts, (f) bacterial phagocytosis by peritoneal leukocytes (%E. coli+ of 
total CD11b+ population), (g) Macrophage efferocytosis in peritoneal exudates were 
assessed. Mean± s.e.m. n=5 mice/group. Two independent experiments. *p<0.05, **p<0.01 
vs. E. coli mice. #p<0.05 vs. naive mice. (h) Mice were inoculated with E. coli (2.5×107 
CFU/mouse); 2h later vehicle (saline+0.1% EtOH) or RvT (as in d–g; 50ng/mouse or 500ng/
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mouse) were administered via i.p. injection and survival assessed. n=10 mice per group. 
Two independent experiments *p<0.05 vs. E. coli mice.
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Figure 4. Atorvastatin and RvT accelerate resolution of infections and promote survival in 
bacterial infections in mice
(a) Mice were inoculated with E. coli (1×105 CFU/mouse) plus RvT (combination of RvT1, 
RvT2, RvT3 and RvT4, ratio of 1:1:1:1, isolated and quantified by RP-UV-HPLC, total 
50ng/mouse). Atorvastatin (0.5μg/mouse; i.p.) or vehicle (saline containing 0.1% EtOH) was 
administered and exudate neutrophil counts (CD11b+Ly6G+) assessed at the indicated time 
points using light microscopy and flow cytometry. Results are mean±s.e.m. n=4 mice per 
group from two independent experiments. **p<0.01 vs. 24h vehicle group. (b) Mice were 
inoculated with E. coli (2.5×107 CFU/mouse); after 3h administered vehicle (Saline+0.1% 
EtOH), 0.5μg/mouse (atorv low dose), 5μg/mouse (atorv high dose) atorvastatin, 0.5μg/
mouse atorvastatin plus 50ng/mouse RvT (atorv low dose plus RvT low dose) or 5μg/mouse 
atorvastatin plus 500ng/mouse RvT (atorv high dose plus RvT high dose); each of the RvT 
was isolated as in panel (a) and survival assessed. n=10 mice per group from three 
independent experiments. *p<0.05, **p<0.01 vs. E. coli mice. #p<0.05 vs. E. coli plus atorv 
low dose mice.
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